---
schema_version: "secwatch.filing_event.v1"
accession: "0001090872-24-000036"
form_type: "8-K"
ticker: "A"
cik: "0001090872"
company_name: "AGILENT TECHNOLOGIES, INC."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:33:52.414983+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "medium"
source: SEC EDGAR
---

# Agilent recasts segment financials moving cell analysis to diagnostics and genomics

## Summary
- Move of cell analysis from life sciences/applied markets to diagnostics/genomics segment effective Q1 FY2024.
- Historical FY2023 data recast in Exhibit 99.1; three reportable segments unchanged.
- No change to Agilent CrossLab segment; recast for comparability only.

## SEC filing metadata
- accession: 0001090872-24-000036
- form_type: 8-K
- ticker: A
- cik: 0001090872
- company_name: AGILENT TECHNOLOGIES, INC.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1090872/000109087224000036/0001090872-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1090872/000109087224000036/a-20240903_d2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001090872-24-000036
- JSON: https://secwatch.observer/filing/0001090872-24-000036.json
- Plain text: https://secwatch.observer/filing/0001090872-24-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.